Breast cancer has become the first female top ten cancer, with an average 19 people every day there is breast cancer. Tradition of pre-menopausal breast cancer patients will be given after tamoxifen anti-hormone therapy to reduce breast cancer recurrence rate. The latest study found that if the use of tamoxifen in patients with no hot flashes, etc. that the effect of poor situation, the proposed formulations with subcutaneous hormone (goserelin), in order to increase breast cancer control rate, to avoid tumor recurrence.
National Cheng Kung University breast surgeon Dr. Chang Choi Wang pointed out that in the treatment of breast cancer, the anti-hormone therapy of estrogen receptor positive are very important in patients with postoperative adjuvant therapy. For pre-menopausal breast cancer patients, the medical community over the years has continued to use tamoxifen as a major anti-hormone therapy drug, and its delay for early breast cancer recurrence and metastasis of breast cancer opportunities; for advanced disease and metastasis of breast cancer suffering can be achieved to narrow the breast tumor and alleviate the effects of the deterioration of many years experience in the use of confirmed into one can reduce the mortality.
Dr. Tsai-wang pointed out that although tamoxifen has its effect, but has long been a lot of patients because of their hot flashes caused by side effects such as disturbed about, or even someone want to stop there. However, according to at American Society of Clinical Oncology and at December journal Lancet published a well-known studies have shown that taking tamoxifen hot flashes have a situation that has to play the efficacy of the drug, which has also become a breast cancer treatment essential drugs at the time of reference.
Choi Chang-wang said that the medical community know the target for the bad effect of the use of tamoxifen, and the proposed merger at the same time subcutaneous hormone preparations (goserelin) the use of injections once a month, allowing access to dormant ovarian status, lower in patients with hormone concentration, help to control tumor cells. According to clinical trials confirmed that agents with subcutaneous hormone (goserelin) can reduce the relapse rate into one. Above all, once about two years after the end of treatment, ovarian function can also return to normal.
Choi Chang-wang said that breast cancer after three years and seven years are the peak period of recurrence of breast cancer, so I propose that it should be immediately after the use of anti-hormone therapy in order to strengthen controls to prevent recurrence of breast cancer; simultaneously study also found that the use of tamoxifen have hot flushes reaction of the body express the relevant enzyme is more activated, the current medical community has been a key gene can be detected CYD2D6, if the enzyme does not belong to the early activation of those agents with subcutaneous hormone (goserelin), in order to grasp the best treatment time.
In addition, tamoxifen because there is thrombosis, endometrial thickening, fatty liver, such as side effects, so for endometrial cancer, thrombosis risk as well as abnormal liver function can also use the subcutaneous hormonal agents (goserelin) in lieu of tamoxifen treatment.
No comments:
Post a Comment